Maritupirdin (Aviander) in case of anxiety disorders: confirmed data and prospects in psychiatry and psychosomatics

Anxiety disorders (AD) are the most common among mental disorders. Anxiety, somatic symptoms, and sleep disorders are characteristic features. Currently, according to various estimates, AD affects from 7.3 % to 28 % of the population, and according to WHO, AD ranks sixth among the causes of disability worldwide. People with AD have a high percentage of comorbidity with somatic diseases, compared with those who do not suffer from anxiety, among which cardiovascular diseases, diabetes mellitus, thyroid diseases, and gastrointestinal disorders are the most common. The relationship between AD and somatic diseases is two-way, since the presence of AD worsens the prognosis of bodily ailments. The article discusses neurotransmitters that somehow participate in the formation of AD, including GABA (γ-aminobutyric acid), norepinephrine, 5-hydroxytryptamine, dopamine, acetylcholine, Neuropeptide Y. The results of studies related to the use of Aviandra in AD, adaptation disorder, are described. The high efficacy and safety of the use of Aviander, which at a dose of 40 mg / day, prescribed for a period of at least 12 weeks, can be a successful treatment strategy for AD, especially in combination with educational programs and cognitive behavioral therapy.